Patients with any known brain or leptomeningeal metastases are excluded, even if treated.
Untreated or symptomatic brain metastases and leptomeningeal disease
Patients with brain metastases (treated or untreated) leptomeningeal disease, uncontrolled seizure disorder, or active neurologic disease
Patients with evidence of active brain metastases, or active leptomeningeal disease are ineligible; patients with a history of brain metastases must have completed treatment (i.e. surgery or radiation) prior to enrollment
Patients with uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
No history or evidence by CT scan or MRI, of brain metastases or leptomeningeal disease.
Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases; asymptomatic or treated brain metastases are acceptable
Uncontrolled brain or leptomeningeal metastases from plexiform neurofibromas, malignant peripheral nerve sheath tumors, or other cancers (other than proven or probable low grade astrocytomas), including patients who continue to require glucocorticoids for control of symptoms related to brain or leptomeningeal metastases
Subjects with known symptomatic brain metastases or leptomeningeal metastases
Any known brain or leptomeningeal metastases are excluded, even if treated.
Have symptomatic brain metastases or leptomeningeal disease
Known brain metastases or leptomeningeal disease involvement. Glioblastoma lesions (primary or locally advanced) are eligible.
Known brain or leptomeningeal metastases
Subject has known symptomatic brain metastases or leptomeningeal involvement as assessed by CT scan or MRI. Subjects with stable asymptomatic brain metastases or leptomeningeal disease are eligible provided that they have not required new treatments for this disease in a 28 day period before the first dose of study drug, and anticonvulsants and steroids have not been administered for a period of 2 weeks prior to the first dose of study drug.
Known symptomatic uncontrolled brain or leptomeningeal metastases (Day 1)
Patients who have known leptomeningeal metastases or untreated or symptomatic brain metastases; treated, asymptomatic brain metastasis can be included
Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases.
Patients who have a primary brain tumor (excluding meningiomas and other benign lesions), any brain metastases, leptomeningeal disease, seizure disorders not controlled with standard medical therapy, or history of stroke within the past year
Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
Current or previously treated brain or leptomeningeal metastases
Current or previously treated brain or leptomeningeal metastases
Clinical evidence of symptomatic progressive brain or leptomeningeal disease during the past 6 months
Known active brain or leptomeningeal metastases (defined as symptomatic metastases) or continued requirement for glucocorticoids for brain or leptomeningeal metastases; treated, asymptomatic metastases are permitted provided the patient has been off steroids for at least 4 weeks prior to day 1 of study drug
Known or suspected leptomeningeal disease; patients with metastases to the brain stem, midbrain, pons or medulla
Untreated brain metastases, treated brain metastases that are not stable, leptomeningeal disease, or seizures uncontrolled with standard medical therapy
Patients who have a primary brain tumor (excluding meningiomas and other benign lesions), any brain metastases, leptomeningeal disease, seizure disorders not controlled with standard medical therapy, history of stroke within the past year
Documented and/or symptomatic or known brain or leptomeningeal metastases
Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
Uncontrolled brain or leptomeningeal metastases, including those who continue to require glucocorticoids for brain or leptomeningeal metastases
Clinical signs of brain involvement or leptomeningeal disease
Untreated brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
Untreated brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
Extensive active brain disease including symptomatic brain metastases or presence of leptomeningeal disease
Patients with symptomatic brain metastases who have not completed radiation therapy and/or are receiving systemic steroid therapy; patients with leptomeningeal disease will be excluded
Brain metastases or active leptomeningeal disease (with the exception of participants with treated epidural disease and no other epidural progression)
The participant has documented brain metastases or leptomeningeal disease.
Confirmed brain and/or leptomeningeal metastases
Patients with known active brain or central nervous system metastases, including leptomeningeal disease; patients with treated and asymptomatic brain metastases may be eligible after discussion with PI
Patients must not have symptomatic uncontrolled brain or leptomeningeal metastases.
Any brain metastases including leptomeningeal metastases, are excluded, even if treated and stable.
Documented or symptomatic brain metastases and/or central nervous system metastases or leptomeningeal disease
Active brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases; treated, asymptomatic metastases are permitted provided the patient has been off steroids for at least 1 month prior to day 1 of study drug
Prior brain or leptomeningeal metastases allowed if asymptomatic (e.g., diagnosed incidentally at study baseline)
Subject has known or suspected primary brain or leptomeningeal metastases
Subject has known symptomatic brain metastases or leptomeningeal involvement as assessed by CT scan or MRI. Subjects with stable asymptomatic brain metastases or leptomeningeal disease are eligible if they have not required new treatments for this disease in a 28 day period before the first dose of study drug, and anticonvulsants and steroids have not been administered for a period of 2 weeks prior to the first dose of study drug.
Brain metastases or leptomeningeal disease
Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
Expansion A:\r\n* Brain metastases or leptomeningeal not previously treated with radiation or surgery
Metastatic brain or leptomeningeal tumors (treated metastatic brain or leptomeningeal tumors are allowed)
Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
A history of or evidence of brain metastases or leptomeningeal disease.
Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
Patients with brain or central nervous system metastases, including leptomeningeal disease
Leptomeningeal disease or any untreated or symptomatic brain metastases, unless the following criteria are met:
Known symptomatic brain mets or leptomeningeal involvement
Known brain, leptomeningeal or epidural metastases (unless treated and well controlled for at least 3 months)
Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
Brain metastases, leptomeningeal disease, uncontrolled seizure disorder, or active neurologic disease
Brain or leptomeningeal metastases that are symptomatic and/or requiring treatment
No known or suspected (associated neurological signs and symptoms) brain metastases (including leptomeningeal involvement)
Patients with brain metastases (treated or untreated) leptomeningeal disease, uncontrolled seizure disorder, or active neurologic disease
Uncontrolled brain metastases or leptomeningeal involvement; patients with brain metastases are permitted if they have received appropriate therapy and demonstrated control of the brain metastases or leptomeningeal disease following therapy; patients with known brain metastases will require magnetic resonance imaging (MRI) brain to demonstrate disease control prior to enrollment (lack of symptom progression for two weeks off therapeutic doses of steroids, excluding chronic steroids used for control of chronic obstructive pulmonary disease [COPD])
Subjects with brain metastases, leptomeningeal disease, uncontrolled seizure disorder, or active neurologic disease
Patients with untreated or uncontrolled brain metastases or leptomeningeal disease
Current or a prior history of brain metastases or leptomeningeal disease. Must not have rapidly progressive, life-threatening metastases.
Symptomatic uncontrolled brain or leptomeningeal metastases
Symptomatic uncontrolled brain or leptomeningeal metastases.
Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
Known brain metastases not radiographically stable for ?3 months or leptomeningeal disease
Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases; treated brain metastases must have been stable for at least 2 months
Uncontrolled brain or all leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
The participant has uncontrolled brain or leptomeningeal metastases
Untreated or symptomatic brain metastases or leptomeningeal disease
Symptomatic, progressive or corticosteroids-requiring documented brain metastases or leptomeningeal disease involvement.